REFERENCES
- WHO Traditional Medicine Strategy 2002-2005. World Health Organization Geneva.
- Zollman C, Vickers AJ. ABC of complementary Medicine London, BMJ Books. 2000.
- Shanmugham LN, Castellani ML, Salini V, Falasca K, Vecchiet J, Conti P, et al. Relevance of lectins in human cell biology and immunology. Riv Biol 2006; 99: 227–247.
- Dang DTN, Eriste E, Liepinsh E, Trinh TT, Erlandsson-Harris H, Sillard R, et al. A novel anti-inflammatory compound, artonkin-4'-0-glucoside, from the leaves of Artocarpus ton kinensis suppresses experimentally in-duced arthritis. 2009; 69: 110–118.
- Uyama H. Artificial polymeric flavonoids: synthesis and applications. Macromol Biosci 2007; 10: 410–422.
- Thuy TT, Kamperdick C, Ninh PT, Lien TP, Thao TT, Sung TV. Immunosuppressive auronol glycosides from Artocarpus tonkinensis. Phar-mazie 2004; 59: 297–300.
- Ngoc DD, Catrina Al, Lundberg K, Harris HE, Ha NT, Anh PT, et al. Inhibition by Artocarpus tonkinensis of the development of collagen-in-duced arthritis in rats. Scand J Immunol 2005; 61: 234–241.
- Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456: 66–72.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J Clin 2008; 58: 71–96
- Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154–1163.
- Redaelli A, Lee JM, Stephens JM, Pashos CL. Epidemiology and clinical burden of acute myeloid leukemia. Expert Rev Anticancer Ther 2003; 3: 695–710.
- Appelbaum FR, Rowe JM, Radich J, Dick JE. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2009;62–86.
- Buchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for con-solidation, and either prolonged maintenance by reduced montly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with the novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003; 21: 4496-4504.
- Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700–708.
- Wahlin A, Billstram R, Bjar O, Ahlgren T, Hedenus M, Haglund M, et al. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. Eur J Hematol 2009; 83: 99–107.
- Romero Al, Thorén FB, Aurelius J, Askarieh G, Brune M, Hellstrand K. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML. Scand J Immunol 2009; 70: 194–205.
- Morris JC, Waldmann TA. Antibody-based therapy of leukaemia. Expert Rev Mol Med 2009; 11: 1–24.
- Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R. The prognostic significance of cytokine levels in newly diag-nosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008; 113: 1605–13.
- Schimdt B, Ribnicky DM, Poulev A, Logendra S, Cefalu WT, Raskin I. A natural history of botanical therapeutics. Metabolism 2008; 57 (7 Suppl 1):S3-9.
- Newman DJ, Cragg GM. Natural products from marine invertebrates and microbes as modulators of antitumor targets. Curr Drug Targets 2006; 7: 279–304.
- Veljkovic J, Hansen U. Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF. Gene 2004; 343: 23–40
- Findlay VJ, Tapiero H, Townsend DM. Sulfiredoxin: a potential therapeutic agent? Biomed Pharmacother 2005; 59: 374–379.
- Mandal P, Pritchard MT, Nagy LE. Anti-inflammatory pathways and alcoholic liver disease: Role of an adiponectin/interleukin-10/heme oxyge-nase-1 pathway. World J Gastroenterol 2010; 16: 1330-1336.
- Miyazaki T, Kirin° Y, Takeno M, Samukawa S, Hama M, Tanaka M, et al. Expression of heme oxygenase-1 in human leukemic cells and its reg-ulation by transcriptional repressor Bachl. Cancer Sci 2010; Epub ahead of print.
- Siva K, Venu P, Mahadevan A, Shankar SK, Inamdar MS. Human BCSA3 expression in embryonic stem cells and vascular precursors suggests a role in human embryogenesis and tumor angiogenesis. PLoS ONE 2007; 2: e1202.